Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:745947.
doi: 10.1155/2012/745947. Epub 2012 Jun 3.

Clinical aspects and management of levodopa-induced dyskinesia

Nicola Tambasco  1 , Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabresi
Affiliations

Clinical aspects and management of levodopa-induced dyskinesia

Nicola Tambasco et al. Parkinsons Dis. 2012.

Abstract

In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with different pharmacological profile are available. Our paper was aimed to analyse the clinical impact and the management of dyskinesias with dopamine agonists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of dopamine agonists on (a) reducing off time, (b) reducing levodopa daily dose, and (c) inducing dyskinesia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. The Lancet Neurology. 2010;9(11):1106–1117. - PubMed
    1. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Movement Disorders. 2008;23(supplement 3):S599–S612. - PubMed
    1. Tambasco N, Belcastro V, Gallina A, Castrioto A, Calabresi P, Rossi A. Levodopa-induced breathing, cognitive and behavioral changes in Parkinson’s disease. Journal of Neurology. 2011:2296–2299. - PubMed
    1. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Movement Disorders. 2008;23(supplement 3):S580–S584. - PubMed
    1. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Archives of Neurology. 2006;63(12):1756–1760. - PubMed

LinkOut - more resources